Opinion
Video
Author(s):
Experts on bladder cancer discusses strategies to minimize adverse effects and the role of immunotherapy in BCG-unresponsive NMIBC treatment paradigms.
UGN-102 data published in Journal of Urology as FDA weighs NMIBC approval
Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care
Sacituzumab govitecan withdrawn from bladder cancer market following negative trial
Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease
FDA accepts new drug application for UGN-102 in NMIBC
Upper tract urothelial carcinoma: An in-depth review for urologists